Drug Type Fusion protein |
Synonyms DR-10628 |
Target |
Mechanism GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 1 | CN | - | |
Metabolic dysfunction-associated steatotic liver disease | Phase 1 | CN | - | |
Obesity | Phase 1 | CN | - | |
Nonalcoholic Steatohepatitis | Preclinical | CN | 04 Jan 2022 |